�Research by scientists at the University of Sheffield suggests that the combination of zoledronic acid (a drug used to preclude bone loss) and chemotherapy agent doxorubicin could full point the emergence of white meat cancer tumours.
Dr Alexis Willett, Policy Manager at Breakthrough Breast Cancer, says:
"Breakthrough welcomes any inquiry which investigates new uses for existing treatments to help benefit people with breast cancer.
"However, it's crucial to think of that this research is at a very early stage and further studies are required before we will know whether this type of approach testament be an effective treatment for women with breast cancer. We await further developments in this region with interest."
Breakthrough Breast Cancer
More info
